Francisco Sánchez is a prominent researcher at Instituto de Química Médica / CSIC, specializing in the design, synthesis, and optimization of organic compounds with therapeutic properties. They have made significant contributions to the development of antitumor drugs, including a new drug currently in clinical Phase II, and played an essential role in obtaining FDA and EMEA clinical trial authorizations. With a PhD in Organic Chemistry from Universidad Autónoma de Madrid, Francisco has authored 14 articles in esteemed scientific journals and holds three patents. They currently serve as a Científico Titular and lead initiatives in drug discovery for neurodegenerative diseases and Chagas disease.
This person is not in the org chart
This person is not in any teams
This person is not in any offices